DYAI

Dyadic InternationalNasdaqCM:DYAI Stock Report

Market Cap

US$150.8m

7D

-6.3%

1Y

-33.4%

Updated

18 Sep, 2021

Data

Company Financials +
DYAI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DYAI Overview

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States.

Share Price & News

How has Dyadic International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DYAI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: DYAI's weekly volatility has increased from 13% to 18% over the past year.


Market Performance


7 Day Return

-6.3%

DYAI

0.5%

US Biotechs

-0.6%

US Market


1 Year Return

-33.4%

DYAI

25.9%

US Biotechs

33.8%

US Market

Return vs Industry: DYAI underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: DYAI underperformed the US Market which returned 33.8% over the past year.


Shareholder returns

DYAIIndustryMarket
7 Day-6.3%0.5%-0.6%
30 Day19.1%5.5%2.0%
90 Day60.3%7.8%4.7%
1 Year-33.4%-33.4%27.5%25.9%35.8%33.8%
3 Year231.5%231.5%20.4%14.9%60.0%50.1%
5 Year280.9%280.9%48.9%37.2%123.0%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Dyadic International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Dyadic International Fundamentals Summary

How do Dyadic International's earnings and revenue compare to its market cap?
DYAI fundamental statistics
Market CapUS$150.79m
Earnings (TTM)-US$11.60m
Revenue (TTM)US$2.16m

69.8x

P/S Ratio

-13.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DYAI income statement (TTM)
RevenueUS$2.16m
Cost of RevenueUS$1.74m
Gross ProfitUS$417.12k
ExpensesUS$12.02m
Earnings-US$11.60m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.42
Gross Margin19.31%
Net Profit Margin-537.10%
Debt/Equity Ratio0.0%

How did DYAI perform over the long term?

See historical performance and comparison

Valuation

Is Dyadic International undervalued compared to its fair value and its price relative to the market?

6.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DYAI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DYAI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DYAI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: DYAI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DYAI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DYAI is overvalued based on its PB Ratio (6.5x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Dyadic International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

8.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DYAI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DYAI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DYAI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DYAI's revenue (21.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: DYAI's revenue (21.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DYAI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Dyadic International performed over the past 5 years?

-34.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DYAI is currently unprofitable.

Growing Profit Margin: DYAI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DYAI is unprofitable, and losses have increased over the past 5 years at a rate of 34.3% per year.

Accelerating Growth: Unable to compare DYAI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DYAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: DYAI has a negative Return on Equity (-50.09%), as it is currently unprofitable.


Financial Health

How is Dyadic International's financial position?


Financial Position Analysis

Short Term Liabilities: DYAI's short term assets ($26.2M) exceed its short term liabilities ($3.3M).

Long Term Liabilities: DYAI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DYAI is debt free.

Reducing Debt: DYAI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DYAI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: DYAI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 21.9% each year


Dividend

What is Dyadic International current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DYAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DYAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DYAI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DYAI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DYAI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.1yrs

Average management tenure


CEO

Mark Emalfarb (65 yo)

16.92yrs

Tenure

US$1,381,633

Compensation

Mr. Mark A. Emalfarb Founded Dyadic International Inc., in 1979 and has been its Chief Executive Officer since October 2004. Mr. Emalfarb has been the President of Dyadic International Inc., since October...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD1.38M) is about average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: DYAI's management team is seasoned and experienced (6.1 years average tenure).


Board Members

Experienced Board: DYAI's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DYAI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Dyadic International, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dyadic International, Inc.
  • Ticker: DYAI
  • Exchange: NasdaqCM
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$150.785m
  • Shares outstanding: 28.08m
  • Website: https://www.dyadic.com

Number of Employees


Location

  • Dyadic International, Inc.
  • 140 Intracoastal Pointe Drive
  • Suite 404
  • Jupiter
  • Florida
  • 33477-5094
  • United States

Listings


Biography

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:12
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.